Array Biopharma Inc (ARRY) Holdings Boosted by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. grew its position in Array Biopharma Inc (NASDAQ:ARRY) by 6.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 575,000 shares of the biopharmaceutical company’s stock after purchasing an additional 35,000 shares during the quarter. Candriam Luxembourg S.C.A. owned approximately 0.28% of Array Biopharma worth $9,384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of ARRY. Schwab Charles Investment Management Inc. boosted its position in shares of Array Biopharma by 22.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 961,894 shares of the biopharmaceutical company’s stock worth $12,313,000 after purchasing an additional 173,892 shares during the period. Fisher Asset Management LLC boosted its position in shares of Array Biopharma by 20.3% in the fourth quarter. Fisher Asset Management LLC now owns 161,433 shares of the biopharmaceutical company’s stock worth $2,066,000 after purchasing an additional 27,253 shares during the period. Handelsinvest Investeringsforvaltning boosted its position in shares of Array Biopharma by 163.2% in the fourth quarter. Handelsinvest Investeringsforvaltning now owns 250,000 shares of the biopharmaceutical company’s stock worth $3,200,000 after purchasing an additional 155,000 shares during the period. Dupont Capital Management Corp boosted its position in shares of Array Biopharma by 20.1% in the fourth quarter. Dupont Capital Management Corp now owns 53,693 shares of the biopharmaceutical company’s stock worth $687,000 after purchasing an additional 8,987 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Array Biopharma by 70.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,244 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 3,834 shares during the period. Institutional investors and hedge funds own 92.55% of the company’s stock.

A number of research firms have weighed in on ARRY. BidaskClub upgraded shares of Array Biopharma from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Zacks Investment Research lowered shares of Array Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, May 14th. Cantor Fitzgerald set a $24.00 price target on shares of Array Biopharma and gave the stock a “buy” rating in a research report on Wednesday, May 9th. ValuEngine upgraded shares of Array Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Finally, Leerink Swann upped their target price on shares of Array Biopharma from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Array Biopharma presently has an average rating of “Buy” and an average target price of $18.00.

Shares of Array Biopharma opened at $15.68 on Wednesday, MarketBeat Ratings reports. The company has a debt-to-equity ratio of 0.36, a current ratio of 5.73 and a quick ratio of 5.73. Array Biopharma Inc has a fifty-two week low of $7.15 and a fifty-two week high of $18.78. The firm has a market cap of $3.32 billion, a P/E ratio of -21.78 and a beta of 1.73.

Array Biopharma (NASDAQ:ARRY) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.11. Array Biopharma had a negative net margin of 72.33% and a negative return on equity of 96.65%. The firm had revenue of $66.37 million during the quarter, compared to analyst estimates of $28.81 million. During the same quarter in the prior year, the business earned ($0.21) earnings per share. Array Biopharma’s revenue for the quarter was up 99.4% on a year-over-year basis. research analysts anticipate that Array Biopharma Inc will post -0.8 earnings per share for the current year.

In related news, Director Lunsen Gil J. Van sold 21,500 shares of the company’s stock in a transaction on Wednesday, April 18th. The shares were sold at an average price of $15.19, for a total transaction of $326,585.00. Following the completion of the transaction, the director now owns 24,797 shares in the company, valued at $376,666.43. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Victor Sandor sold 156,016 shares of the company’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $17.71, for a total transaction of $2,763,043.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 229,205 shares of company stock valued at $3,913,585. 3.18% of the stock is owned by company insiders.

Array Biopharma Company Profile

Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.

Want to see what other hedge funds are holding ARRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Array Biopharma Inc (NASDAQ:ARRY).

Institutional Ownership by Quarter for Array Biopharma (NASDAQ:ARRY)

Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply